Helixgate

Helixgate

Uncategorized

AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee

Published

on

Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of mutation detection, as opposed to the current practice of changing regimens upon disease progression.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

PFAS is still in some infant formula

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Continue Reading

Uncategorized

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Published

on

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.

In patients with a …

Continue Reading

Uncategorized

Amgen positions MariTide as potential ‘best monthly’ obesity drug

Published

on

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.

Continue Reading
Advertisement

Trending